Show Summary Details
Page of

Vasculitides and fibromuscular dysplasia 

Vasculitides and fibromuscular dysplasia
Vasculitides and fibromuscular dysplasia

Catherine Hill

, Scott Graf

, and Robert Fitridge

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 05 July 2020

Vasculitides are a group of related diseases that are characterized by histological evidence of inflammatory leucocytes in vessel wall with reactive damage to mural structures. Vasculitides are often serious and may be life threatening. Therefore, early diagnosis and treatment is imperative to ensure the best patient outcome. Although the distribution of affected organs may suggest a certain type of vasculitis, there is significant overlap between them. Early treatment, in most cases glucocorticoids and immunosuppressants, has improved outcomes. However, vasculitides can relapse, requiring further or maintenance therapy. Long-term complications may result from adverse effects of treatment or vascular injury due to scarring and stenosis of affected vessels. The latter may lead to ischaemia or vessel rupture that may not necessarily reflect active vasculitis. Early deaths are generally due to active vasculitis with late deaths, predominantly due to complications of therapy. This chapter will outline the pathogenesis, clinical features, and principles of management of vasculitides and fibromuscular dysplasia.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.